Healthcare

• The company executed an exclusive OCU400 license agreement for the Middle East and North Africa with Roots Pharmaceutical, its second regional deal.

• Odyssey completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor targeting innate immune pathways.

• Phase 3 MANGROVE data showed a 43% reduction in the risk of progression or death versus bendamustine plus rituximab

• The repeat order follows successful delivery of the first dataset under a previously announced multi-modal imaging data agreement.

• Adjusted EBITDA grew 4.3% to $124.6 million, while adjusted diluted EPS increased 8.9% to $0.49.

• The company is advancing VT-7208, a next-generation oral Bruton's tyrosine kinase inhibitor, in planned Phase 2 programs for food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis.

• Bempikibart demonstrated a mean 35.3% reduction in SALT score from baseline at Week 36, with 40.0% of patients achieving SALT-20 response in the mITT analysis.